Therapie des duktalen Pankreaskarzinoms in einem immunkompetenten Rattenmodell: Suramin unterdrückt Primärtumorwachstum und Metastasierung nahezu vollständig

Abstract

A previous study demonstrated that Suramin, a naphthyl urea derivative, reduces the proliferation of human pancreas carcinoma cells in vitro. The aim of the present study was to examine the effect of Suramin on tumor growth and metastasis in vivo using a clinically relevant orthotopic immunocompetent rat model of pancreatic cancer. 1 mm³ tumor-fragments of the ductal rat-pancreatic cell line DSL-6A/C1 were orthotopically implanted into the pancreas of 16 Lewis-rats. The animals were randomized into therapy group (n = 8, Suramin 60 mg/kg, weekly i. p.) and control-group (n = 8). 4 weeks after implantation, intravital microscopy was performed, and the tumor volume and metastasis were determined at autopsy. The animals of the control-group developed large tumors with local infiltration and metastasis. In contrast, half of the animals of the therapy-group showed no tumor growth, the other half developed only small tumors without metastasis. In conclusion, Suramin reduces primary tumor growth and dissemination in the early stage of tumor development in an immunocompetent rat model of pancreatic cancer.